retatrutide triple agonist clinical trial hormone receptor for obesity Phase 2 of Triple Agonism Based Therapies for – Triple Agonism Based Therapies for

The Metsera acquisition suggests Pfizer believes metabolic disease is a priority area to become a top-tier business we should watch Pfizers pipeline for new obesity/metabolism projects (possibly built via smaller partnerships)

This demonstrates that the injectable route produces body-wide regenerative enhancement rather than just local effects at the injection site

I have previously summarised the therapeutic pipeline for MASH (see links below) and in the past year we have seen the approval of Resmetirom, and now Semaglutide / ozempic is showing very impressive data in a Ph3 trial

A single bout of vomiting can deplete more potassium than an entire banana replaces